Abstract:Introduction: Cardiac hypertrophy is characterized by significant metabolic changes, notably an increase in glycolysis. Histone lactylation, a post-translational modification influenced by the glycolytic state of cells, plays a crucial role in regulating gene transcription. However, the relationship between histone lactylation and cardiac hypertrophy remains unclear. Research Questions: This study aims to elucidate the effects and underlying mechanisms of histone lactylation in the progression of cardiac hypertrophy induced by pressure overload. Methods and Results: We observed an increase in histone lactylation levels in hypertrophic hearts from both humans and mice. To investigate further, male mice underwent transverse aortic constriction (TAC) to induce cardiac hypertrophy, followed by either an intraperitoneal injection of Oxamate (an LDHA inhibitor) to reduce histone lactylation or sodium lactate to increase it. Reducing histone lactylation protected the hearts from TAC-induced hypertrophy and fibrosis, preserving cardiac function, while increased histone lactylation exacerbated cardiac hypertrophy and fibrosis, impairing cardiac function. Cardiomyocyte-specific deletion of LDHA also led to a reduction in cardiac hypertrophy. In vitro experiments showed that inhibiting histone lactylation reduced the expression of hypertrophic markers and the hypertrophic growth of cardiomyocytes stimulated by phenylephrine. Using co-immunoprecipitation, we confirmed that P300 and GCN5 are the transferases mediating histone lactylation in cardiomyocytes. Mechanistic studies using the CUT&Tag technique revealed lactate-dependent histone modification was enriched at the promoter of TGFB2, activating its transcription. Inhibiting cardiac-specific TGFB2 expression through adeno-associated viral delivery of shRNA reduced TAC-induced cardiac hypertrophy. Furthermore, TGFB2 overexpression induced a hypertrophic phenotype in cardiomyocytes and activated the PI3K/AKT/mTOR pathways. This hypertrophic phenotype, induced by TGFB2 overexpression, was suppressed by inhibitors of PI3K or AKT. Conclusion: Our findings reveal a critical role for histone lactylation in the development of pathological cardiac hypertrophy by regulating TGFB2 expression and the PI3K/AKT/mTOR pathway.

Histone H4R3 symmetric di-methylation by Prmt5 protects against cardiac hypertrophy via regulation of Filip1L/β-catenin.

PRMT5 Prevents Cardiomyocyte Hypertrophy Via Symmetric Dimethylating HoxA9 and Repressing HoxA9 Expression

Inhibition of Histone Demethylase JMJD1C Attenuates Cardiac Hypertrophy and Fibrosis Induced by Angiotensin II

PRMT5 up-regulation improves myocardial hypertrophy by mediating E2F-1/NF-κB/NLRP3 pathway

Abstract 4134695: the Effect and Mechanism of Histone Lactylation in Pathological Cardiac Hypertrophy Induced by Pressure Overload

Abstract 655: Protein Arginine Methyltransferase 6 Controls Cardiac Hypertrophy by Differential Arginine and Lysine Methylation of Histone H3

Fibroblast-specific PRMT5 deficiency suppresses cardiac fibrosis and left ventricular dysfunction in male mice

Loss of M6a Methyltransferase METTL5 Promotes Cardiac Hypertrophy Through Epitranscriptomic Control of SUZ12 Expression

Abstract 9529: METTL3 Mediates Ang-II Induced Cardiac Hypertrophy Through Accelerating Pri-miR-221/222 Maturation in M6a Way

Histone lysine dimethyl-demethylase KDM3A controls pathological cardiac hypertrophy and fibrosis

METTL3 Mediates Ang-II-induced Cardiac Hypertrophy Through Accelerating Pri-Mir-221/222 Maturation in an M6a-Dependent Manner

MYH7 R453C induced cardiac remodelling via activating TGF-β/Smad2/3, ERK1/2 and Nox4/ROS/NF-κB signalling pathways

The Histone Demethylase PHF8 Represses Cardiac Hypertrophy Upon Pressure Overload.

PRMT5 Prevents Dilated Cardiomyopathy via Suppression of Protein O-GlcNAcylation

Mechanism of histone deacetylases in cardiac hypertrophy and its therapeutic inhibitors

Epigenetic Regulation of Cardiomyocyte Maturation by Arginine Methyltransferase CARM1

The m7G Methyltransferase Mettl1 Drives Cardiac Hypertrophy by Regulating SRSF9‐Mediated Splicing of NFATc4

The piRNA CHAPIR regulates cardiac hypertrophy by controlling METTL3-dependent N6-methyladenosine methylation of Parp10 mRNA

Reduced DNMT1 Levels Induce Cell Apoptosis Via Upregulation of METTL3 in Cardiac Hypertrophy

Targeting JMJD3 histone demethylase mediates cardiac fibrosis and cardiac function following myocardial infarction

The functional role of m6A demethylase ALKBH5 in cardiomyocyte hypertrophy